Blue Ocean Capital Group (“BOCG”) is a life science focused venture capital investment firm and has carried out investments in the innovative biotech hubs of Greater China, U.S.A and selected countries in Europe.

BOCG is committed to driving the transformation of biotechnology and empowering the development of innovative enterprises, leveraging its tremendous experience, extensive industrial network, and scientific research resources. Since its founding in late 2015, BOCG has invested in various innovative biotech and medical device companies with US$300+ million in cumulative capital commitments.

BOCG is more than an investment firm, but also a dynamic platform to promote ESG and fuel the most innovative companies. As a signatory to the United Nations-supported Principles for Responsible Investment ("UN PRI"), BOCG is devoted to responsible investment and empowers sustainable development of the portfolio companies.

Widely recognized within the industry, BOCG has received a number of well-known awards by institutions such as ChinaVenture, FoF Weekly, 36kr and CHC & CITIC Securities, etc. Recently, BOCG was named a "Top 10 Impact Investment Institution" by 2023 For Good Awards.